Subtopic Deep Dive
Direct-Acting Antiviral Therapy for HCV
Research Guide
What is Direct-Acting Antiviral Therapy for HCV?
Direct-Acting Antiviral (DAA) therapy for HCV uses small-molecule inhibitors targeting viral proteins to achieve sustained virologic response in patients infected with hepatitis C virus.
DAAs like sofosbuvir and ledipasvir replaced interferon-based regimens, yielding cure rates over 95% across genotypes (Afdhal et al., 2014). Key trials demonstrated efficacy in untreated genotype 1 patients with 12-week ledipasvir-sofosbuvir regimens (Afdhal et al., 2014; 1693 citations). Over 20 papers in the list address DAA outcomes, resistance, and retreatment (Zeuzem et al., 2011).
Why It Matters
DAA therapy transformed HCV from a chronic condition to a curable disease, reducing global burden and preventing hepatocellular carcinoma (Llovet et al., 2021). Real-world applications include pan-genotypic regimens effective against diverse HCV genotypes prevalent worldwide (Messina et al., 2014). AASLD-IDSA guidelines recommend DAAs for all infected adults, improving access in resource-limited settings (AASLD-IDSA HCV Guidance Panel, 2015). Retreatment strategies with telaprevir boosted response rates in prior non-responders (Zeuzem et al., 2011).
Key Research Challenges
HCV Genotype Diversity
HCV's seven genotypes with regional prevalence complicate pan-genotypic DAA development (Messina et al., 2014; 1560 citations). Genotype-specific responses require tailored regimens, as seen in ledipasvir-sofosbuvir trials for genotype 1 (Afdhal et al., 2014). Global mapping reveals genotype 3 dominance in South Asia, hindering universal therapies.
DAA Resistance Profiles
Resistance-associated variants emerge in retreatment failures, reducing efficacy of NS3/4A inhibitors like telaprevir (Zeuzem et al., 2011; 1533 citations). Baseline RAS testing guides regimen selection per AASLD guidelines (AASLD-IDSA HCV Guidance Panel, 2015). Monitoring post-treatment resistance aids salvage therapies.
Real-World Outcome Variability
Clinical trials show high SVR, but real-world data reveal gaps in cirrhotic or co-infected patients (Ghany et al., 2011). Factors like adherence and comorbidities impact cure rates beyond ION-1 trial results (Afdhal et al., 2014). Guidelines emphasize patient-specific retreatment strategies (Strader et al., 2004).
Essential Papers
Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva et al. · 2021 · Nature Reviews Disease Primers · 6.0K citations
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · 2018 · Hepatology · 4.1K citations
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jonas consults for Gile...
Type I interferons in infectious disease
Finlay W. McNab, Katrin D. Mayer-Barber, Alan Sher et al. · 2015 · Nature reviews. Immunology · 2.6K citations
Diagnosis, management, and treatment of hepatitis C†
Doris B. Strader, Teresa L. Wright, David L. Thomas et al. · 2004 · Hepatology · 1.7K citations
HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HIV, human immunodeficiency virus; anti-HCV, HCV antibody; RNA, ribonucleic acid; PCR, polymerase chain react...
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo et al. · 2014 · New England Journal of Medicine · 1.7K citations
Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection. (Funded by Gilead Sciences; ION-1 ...
Global distribution and prevalence of hepatitis C virus genotypes
Jane P. Messina, Isla Humphreys, Abraham D. Flaxman et al. · 2014 · Hepatology · 1.6K citations
Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence. This poses a challenge to the improved development of vaccines and pan‐genotypi...
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem, Pietro Andreoné, Stanislas Pol et al. · 2011 · New England Journal of Medicine · 1.5K citations
Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was...
Reading Guide
Foundational Papers
Start with Strader et al. (2004; Hepatology, 1716 citations) for pre-DAA diagnostics, then Afdhal et al. (2014; NEJM, 1693 citations) for ledipasvir-sofosbuvir pivotal trial establishing >95% SVR benchmark, and Zeuzem et al. (2011) for first-generation DAA retreatment.
Recent Advances
AASLD-IDSA HCV Guidance Panel (2015; Hepatology, 1377 citations) for current pan-genotypic recommendations; Llovet et al. (2021; Nature Reviews Disease Primers, 5996 citations) links DAAs to HCC risk reduction; Ghany et al. (2011) updates genotype 1 practices.
Core Methods
Fixed-dose combinations (sofosbuvir/ledipasvir 12 weeks); SVR measurement by PCR (Strader et al., 2004); genotype sequencing for pan-genotypic design (Messina et al., 2014); resistance-guided retreatment (Zeuzem et al., 2011).
How PapersFlow Helps You Research Direct-Acting Antiviral Therapy for HCV
Discover & Search
Research Agent uses searchPapers and exaSearch to find DAA efficacy studies, then citationGraph on Afdhal et al. (2014) reveals 1693 citing papers on ledipasvir-sofosbuvir outcomes; findSimilarPapers expands to sofosbuvir trials across genotypes.
Analyze & Verify
Analysis Agent applies readPaperContent to extract SVR rates from Afdhal et al. (2014), verifies claims with CoVe against AASLD guidelines (AASLD-IDSA HCV Guidance Panel, 2015), and runs PythonAnalysis on pandas for meta-analysis of genotype response data with GRADE evidence grading.
Synthesize & Write
Synthesis Agent detects gaps in pan-genotypic coverage from Messina et al. (2014), flags contradictions in resistance data; Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 20+ DAA papers, and latexCompile for review manuscripts with exportMermaid for treatment flowcharts.
Use Cases
"Run meta-analysis of SVR rates from DAA trials for HCV genotype 1"
Research Agent → searchPapers('ledipasvir sofosbuvir SVR') → Analysis Agent → readPaperContent(Afdhal 2014) + runPythonAnalysis(pandas meta-analysis of 5 trials) → GRADE-graded CSV export of pooled 94% SVR (95% CI).
"Draft LaTeX review on DAA retreatment strategies"
Synthesis Agent → gap detection(Zeuzem 2011 telaprevir) → Writing Agent → latexEditText(12-page draft) → latexSyncCitations(15 HCV papers) → latexCompile → PDF with resistance profile diagrams.
"Find open-source code for HCV genotype prevalence modeling"
Research Agent → searchPapers('HCV genotypes Messina 2014') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → R script for global prevalence maps from 1560-cited dataset.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ DAA papers: searchPapers → citationGraph(Afdhal 2014) → DeepScan(7-step verification with CoVe checkpoints) → structured report on SVR meta-analysis. Theorizer generates hypotheses on resistance evolution from Zeuzem et al. (2011) + Messina et al. (2014). DeepScan analyzes real-world gaps versus trial data (Ghany et al., 2011).
Frequently Asked Questions
What defines Direct-Acting Antiviral therapy for HCV?
DAAs are small-molecule drugs targeting HCV NS3/4A protease, NS5A, or NS5B polymerase, achieving SVR12 >95% without interferon (Afdhal et al., 2014).
What are key methods in DAA research?
Phase 3 trials like ION-1 test fixed-dose combinations (ledipasvir-sofosbuvir) for 12-24 weeks; resistance testing uses NS5A RAS sequencing (AASLD-IDSA HCV Guidance Panel, 2015).
What are seminal papers on DAAs?
Afdhal et al. (2014; NEJM, 1693 citations) showed 99% SVR for untreated genotype 1; Zeuzem et al. (2011; NEJM, 1533 citations) established telaprevir retreatment efficacy.
What open problems remain in DAA therapy?
Acute HCV treatment shortening, pediatric dosing, and access in low-resource settings with genotype diversity (Messina et al., 2014); retreatment for multi-DAA failures lacks consensus.
Research Hepatitis C virus research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Direct-Acting Antiviral Therapy for HCV with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hepatitis C virus research Research Guide